Drugs and patents in ATC class A02B - DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

Last updated: July 26, 2026

ATC A02B (drugs for peptic ulcer and gastro-oesophageal reflux disease) is dominated by acid-suppression therapies, with proton pump inhibitors (PPIs) accounting for the majority of market share and ongoing profit pools concentrated in branded/refillable formulations, combination products, and line extensions. The patent landscape is largely matured at the API level, but remains active around formulation design, dosing regimens, and method-of-treatment claims, creating pockets of delayed generic entry even where active ingredient patents expired years earlier.

High-level market-patent reality check:

Most first-generation PPI active ingredient patents are expired in major markets, driving sustained generic competition.
Residual exclusivity is increasingly tied to new formulations (IR/EC choices, delayed release, oral suspension, granules), fixed-dose combinations, and indication and dosing regimen patents.
Litigation and Paragraph IV challenges are concentrated where Orange Book “listed” patents still protect specific products or combinations rather than the underlying API.

Core APIS within A02B (typical coverage in major markets):

PPIs: omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole
H2RA (smaller share in A02B): famotidine
Mucosal agents and anti-ulcer adjuncts: sucralfate, bismuth compounds (varies by country classification), and other gastroprotectives depending on local ATC mapping

Because the request is for the patent landscape and market dynamics across the entire ATC class, the analysis below is structured to match how enforcement and entry barriers actually occur: by API maturity, formulation/combination residual IP, and regulatory exclusivity + Orange Book listing mechanics.

Which drugs dominate ATC A02B market share and where are the remaining patent barriers?

Featured snippet answer: Market share in A02B is concentrated in PPIs, while remaining barriers are concentrated in product-specific Orange Book listings and formulation/combination patents, not in primary API composition-of-matter patents.

Market dynamics by drug subsegment (PPI vs non-PPI)

PPIs (core volume, price pressure)
- Generic penetration is high in most geographies.
- Branded share persists where companies retain protection via:
  - Extended-release / dual delayed-release (e.g., dexlansoprazole-type concepts)
  - Oral disintegrating tablets, capsules with specific bead layering, granules/sachets
  - Combination therapy line extensions
- Competitive pressure compresses margins, shifting value toward:
  - payer contracts
  - formulary placement
  - controlled-release differentiation
  - patient adherence programs
H2 receptor antagonists and adjunct gastroprotectives (niche and regional)
- Less protected by large estates relative to PPIs.
- Remaining IP often relates to specific formulations or method-of-use in defined populations (e.g., night dosing, prophylaxis subsets).
Specialty segments within GERD
- Treatment of refractory GERD, erosive esophagitis, and step-up/step-down regimens can create method-of-use patent strategies.
- Pediatric and elderly dosing can drive formulation patents (stability and dosing accuracy) and exclusivity claims where applicable.

Where patent barriers persist in 2024 to 2026

Patent “last mile” in A02B typically comes from one or more of:

Formulation patents: protective shell, release timing, bead technology, granule suspension attributes.
Method-of-use patents: optimized dosing schedules, titration algorithms, or GERD maintenance dosing.
Device-adjacent or delivery system patents: less common for PPIs but can appear for novel oral forms.
Combination products: PPI paired with other actives (e.g., specific anti-H. pylori regimens, antacids, anti-spasmodics depending on market-specific authorizations).

How do PPI patent estates differ by active ingredient (omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole)?

Featured snippet answer: Patent estates for classic PPIs are mostly expired, but dexlansoprazole-type differentiated release systems and product-specific formulation patents create the most persistent residual protection.

Composition-of-matter maturity

First-wave originators (including early omeprazole/lansoprazole/rabeprazole/pantoprazole families) have largely passed composition-of-matter and core process patent milestones.
Generic entry is typically enabled unless:
- Orange Book lists product-specific patents tied to the applicant’s NDA/ANDA reference product
- Residual exclusivity (data exclusivity, pediatric exclusivity where applicable) still blocks certain FDA references

Persistent IP patterns by “generation”

Earlier PPIs
- Residual protection usually narrower:
  - specific salt/crystal forms where still relevant
  - formulation and manufacturing process patents that are product-labeled
Later differentiated PPIs
- Estates more likely to include:
  - release profile patents
  - claims covering dual delayed-release dosing behavior (where applicable)
  - lifecycle filings for pediatric formulations or new strengths

Strategic implication

For litigation and entry timing, the most decision-relevant question is not “does the API have patents,” but:

Which listed Orange Book patents attach to the exact NDA/strength/dosage form the applicant references?
Which of those patents support an enforceable exclusivity block vs a weak, non-listed, or easy-to-design-around claim set?

When does ATC A02B exclusivity end for each branded product category, and how does it affect generic launches?

Featured snippet answer: Exclusivity ends when the last relevant Orange Book-listed patent and any applicable regulatory exclusivity expire for the specific listed product, enabling generic FDA approval and launch (absent injunction or settlement).

Exclusivity mechanics that matter for A02B

Patents
- Patent expiry is not sufficient by itself.
- The generics risk hinges on whether the ANDA is blocked by:
  - Paragraph IV litigation stay/trigger windows
  - court injunctions
  - settlement agreements (often “pay-for-delay” style or “no-early-entry” agreements)
Regulatory exclusivity
- Data exclusivity (NDA-specific) and pediatric exclusivity can add time but is less dominant for older PPI products in major markets.
- For newer line extensions (formulations, fixed-dose combos, new strengths or delivery systems), exclusivity can matter if the regulatory pathway creates new exclusivity categories.

Generic launch timing in practice

Most A02B generics can launch quickly after:

final listed patent expiry
resolution of Paragraph IV litigation
settlement end dates

Where delayed entry persists, it is typically because:

the listed patent set includes formulation/method claims and/or
settlements specify contractually delayed launch.

What patents protect omeprazole/esomeprazole/pantoprazole/lansoprazole/rabeprazole/dexlansoprazole products in the Orange Book?

Featured snippet answer: Orange Book protection for PPIs generally clusters into:

formulation and dosage form patents
method-of-use patents tied to GERD indications or maintenance dosing
process/manufacturing patents supporting the product as marketed

Typical claim clusters seen in A02B filings

Because A02B is mature, claim clusters that repeatedly appear in remaining enforceable estates include:

1) Formulation and release profile patents

enteric coating parameters
bead/granule layering
dissolution profile targets
stability for specific oral presentations

2) Method-of-use patents

GERD treatment regimens
maintenance therapy schedules
patient stratification or titration approach

3) Combination product patents

co-administration regimens
fixed-dose combinations with defined dosing timing

What this means for generic entrants

Generic applicants often pursue one of three strategies:

design-around formulation/method claims to avoid infringement
wait out specific listed patents and challenge only later ones
negotiate settlements to avoid litigation risk

How many Paragraph IV patent challenges exist in A02B, and where are they concentrated?

Featured snippet answer: Paragraph IV challenges cluster in A02B around still-listed product-specific patents for branded PPI formulations and combinations, not around the expired core API.

Concentration drivers

Orange Book listing breadth
- products with many listed patents see more challenge targets
Short runway
- brands with patent expiry dates in a 2 to 4 year window attract multiple ANDA filings
Manufacturing complexity
- if the branded formulation is hard to reproduce, infringement arguments become more plausible

Litigation risk profile

A02B disputes tend to be less “bet-the-company” than oncology due to:
- multiple alternative products in-market
- high generic substitution
But they can still be material because GERD PPIs can generate high unit volumes if a product becomes the low-cost default through payer contracts.

Which companies are challenging A02B patents and which originators are enforcing?

Featured snippet answer: Challengers are typically generic and biosimilar-adjacent large ANDA filers plus established regional players; originator enforcement is mainly by PPI brand holders and their lifecycle owners of formulation and method-of-use patents.

Typical enforcement posture

originator companies focus on:
- injunction leverage early
- claim construction and infringement posture
- settlement for non-infringement or delayed entry scenarios

Market consequences

settlements can quickly shift payer behavior and wholesale inventory planning
litigation outcomes determine which ANDA “wins” the next product cycle

(A company-by-company listing with case citations requires product-level patent and litigation docket data; without docket-specific data for all A02B products, any named list would be incomplete.)

What is the Orange Book status of A02B products, and how does it map to FDA approval timing?

Featured snippet answer: Orange Book status is the gating factor for FDA eligibility and launch timing in A02B; the last expiring listed patent typically dictates whether ANDA approval triggers can lead to immediate marketing.

Orange Book to launch timeline mapping

ANDA approval date
- does not equal launch date if litigation or settlement blocks marketing
Paragraph IV notice
- triggers litigation clock and can trigger a statutory stay
Court outcomes
- either lift the block or force design-around and relaunch later
Settlement
- can create a contractually defined entry date even after some patents expire, depending on the agreement terms

How do formulation patents affect generic entry for GERD PPIs and what barriers are hardest to design around?

Featured snippet answer: The hardest-to-design-around barriers in A02B are release profile claims and specific enteric coating/particle layering linked to marketed dosage forms.

Hard barriers

Dual or delayed-release behavior
dissolution profile targets
manufacturing steps that are functionally tied to claim elements

Easier-to-design-around barriers

broad method claims without tight regimen limitations
generic formulations that can meet functional equivalence while altering non-essential process steps
patents that are not listed to block the exact NDA strength/dosage form referenced by an ANDA

What patent litigation affects ATC A02B, and how do settlements change the competitive landscape?

Featured snippet answer: Litigation affects A02B primarily by shifting launch dates for generic PPIs from “patent expiry” to “settlement end date” for the specific strength/dosage form in dispute.

Common settlement patterns in A02B

delayed entry until a certain month/year
market allocation or launch sequencing agreements
carve-outs tied to specific strengths or dosage forms

Competitive landscape impact

early entrants gain formulary momentum
later entrants accept lower share due to payer lock-in and pharmacy stocking inertia

How does biosimilar risk apply to ATC A02B (and why it is usually irrelevant)?

Featured snippet answer: Biosimilar risk is generally irrelevant for A02B because the class is dominated by small-molecule PPIs and related oral therapies, not biologics.

What formulations are protected by ATC A02B patents (capsules, tablets, granules, oral suspension)?

Featured snippet answer: Protection concentrates on:

enteric-coated tablets/capsules
capsule bead layering or granule release profiles
oral suspension and pediatric-friendly presentations where stability and dosing accuracy are claimed

Dosage form categories with recurring patent coverage

delayed-release capsules
enteric-coated tablets
granules/sachets
orally disintegrating or chewable formats (where marketed)
strength-specific claims (e.g., pediatric or maintenance strengths)

Which generic entry risks exist for ATC A02B drugs by scenario (launch at expiry, design-around, or settlement-limited entry)?

Featured snippet answer: Generic entry risk is highest in scenarios where a challenger relies on a fast launch at API expiry but the branded product still has enforceable listed formulation/method patents for the exact dosage form and strength.

Three generic launch scenarios

Launch-at-expiry
- risk: a still-listed formulation patent extends the effective exclusivity window
Design-around
- risk: doctrine of equivalents or functional claim interpretation
Settlement-limited entry
- risk: product-specific agreement constraints reduce upside despite FDA approval

How does ATC A02B compare with other acid-suppression classes (A02B vs A02D/A02C) in IP intensity and competition?

Featured snippet answer: A02B’s IP intensity is driven by mature small-molecule lifecycle strategies, while competing classes show different risk profiles depending on whether they contain biologics or device-driven therapies.

Practical comparative takeaway

A02B behaves like a mature branded-to-generic transition market with residual lifecycle patents.
Competition is usually price-based once patents clear, not efficacy-based, except in differentiated release formulations.

Key tables: what drives value in A02B today

Table 1: Patent-to-commercial value mapping for PPIs in A02B

Value driver	Patent category	Typical listed claim themes	Generic design-around difficulty	Launch impact
Maintaining branded shelf share	Formulation + release profile	delayed/dual delayed release, enteric coating, dissolution targets	High when functional profile is claimed tightly	Delays generic marketing even after API expiry
Prolonging maintenance market	Method-of-use	maintenance dosing regimens, refractory GERD	Medium to high	Blocks or narrows indication-based competition
Protecting pediatric offerings	Dosage form presentation	stability, dosing uniformity, granule/suspension characteristics	Medium	Blocks pediatric-specific formulations and schedules
Blocking fixed-dose alternatives	Combination	co-administration timing and regimen claims	Medium	Restricts generic access to the branded regimen

Table 2: Market outcome by legal/ regulatory gating event

Event	What changes	Competitive outcome
Orange Book last listed patent expiry	FDA approval may enable marketing	Rapid price compression if no injunction
Paragraph IV litigation loss by challenger	Marketing blocked (or delayed)	Brand holder retains share and payer positioning
Settlement agreement	Launch date contractually set	Entry shifts from “expiry date” to “settlement date”
New formulation lifecycle patent	Strength/dosage form exclusivity persists	Substitution may shift to other strengths or dosage forms

Key Takeaways

ATC A02B is structurally a mature small-molecule market with PPIs dominating volume; core API composition-of-matter protections are mostly expired.
Residual exclusivity and infringement risk persist through Orange Book-listed formulation, release profile, and method-of-use patents tied to specific NDA/strength/dosage forms.
Generic entry risk is product-specific: challengers must assess the exact listed patents that attach to the referenced branded product, not just API expiry.
Paragraph IV disputes and settlements are the main determinants of effective exclusivity in the late lifecycle, shifting launch timing from statutory expiry to litigation/contract endpoints.

FAQs

1) What Orange Book patents matter most for GERD PPIs?
Product-specific formulation/release profile and method-of-use patents tied to the exact NDA/strength/dosage form generally drive enforceable blocks.

2) Do PPI API patent expirations automatically allow generic launch?
No. Marketing is blocked if any Orange Book-listed patent remains in force for the referenced product or if litigation/settlements delay entry.

3) Are biosimilar pathways relevant to ATC A02B?
Typically no. ATC A02B is dominated by small-molecule oral therapies rather than biologics.

4) Which dosage forms are most commonly protected in GERD lifecycle patents?
Enteric-coated delayed-release and release-profile dosage forms (capsules/tablets) and pediatric-friendly presentations (granules/oral formulations) are common targets.

5) What is the most common reason a generic launch is delayed after FDA approval?
An unresolved patent injunction or settlement that contractually limits launch timing for the disputed strength/dosage form.

References

(No sources were provided in the prompt, and no product-specific Orange Book, patent, or litigation docket citations can be accurately enumerated across the full ATC A02B class without external datasets. Per instruction constraints, citations are omitted.)

Subclasses in ATC: A02B - DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)